These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 23988873)

  • 21. Complete DPYD genotyping combined with dihydropyrimidine dehydrogenase phenotyping to prevent fluoropyrimidine toxicity: A retrospective study.
    De Metz C; Hennart B; Aymes E; Cren PY; Martignène N; Penel N; Barthoulot M; Carnot A
    Cancer Med; 2024 Mar; 13(6):e7066. PubMed ID: 38523525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.
    Meulendijks D; Henricks LM; Jacobs BAW; Aliev A; Deenen MJ; de Vries N; Rosing H; van Werkhoven E; de Boer A; Beijnen JH; Mandigers CMPW; Soesan M; Cats A; Schellens JHM
    Br J Cancer; 2017 May; 116(11):1415-1424. PubMed ID: 28427087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil].
    Ostapowicz A; Dołegowska B
    Przegl Lek; 2012; 69(9):694-7. PubMed ID: 23401991
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?
    Meulendijks D; Cats A; Beijnen JH; Schellens JH
    Cancer Treat Rev; 2016 Nov; 50():23-34. PubMed ID: 27589829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU- and capecitabine-related toxicity using full sequencing of DPYD.
    Saif MW
    Cancer Genomics Proteomics; 2013; 10(2):89-92. PubMed ID: 23603345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Joint Belgian recommendation on screening for DPD-deficiency in patients treated with 5-FU, capecitabine (and tegafur).
    Casneuf V; Borbath I; Van den Eynde M; Verheezen Y; Demey W; Verstraete AG; Bm Claes K; Haufroid V; Geboes KP
    Acta Clin Belg; 2022 Apr; 77(2):346-352. PubMed ID: 33423619
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant.
    De Falco V; Natalicchio MI; Napolitano S; Coppola N; Conzo G; Martinelli E; Zanaletti N; Vitale P; Giunta EF; Vietri MT; Vitiello PP; Ciardiello D; Marinaccio A; De Vita F; Ciardiello F; Troiani T
    Medicine (Baltimore); 2019 May; 98(21):e15759. PubMed ID: 31124962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time.
    Lunenburg CATC; Henricks LM; Guchelaar HJ; Swen JJ; Deenen MJ; Schellens JHM; Gelderblom H
    Eur J Cancer; 2016 Feb; 54():40-48. PubMed ID: 26716401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Severe capecitabine-associated toxicity in a patient carrying a mutation in the dihydropyrimidine dehydrogenase gen].
    González-Haba E
    Farm Hosp; 2012; 36(6):554-5. PubMed ID: 23461455
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmacogenetics of DPYD and treatment-related mortality on fluoropyrimidine chemotherapy for cancer patients: a meta-analysis and trial sequential analysis.
    de Moraes FCA; de Almeida Barbosa AB; Sano VKT; Kelly FA; Burbano RMR
    BMC Cancer; 2024 Sep; 24(1):1210. PubMed ID: 39350200
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio.
    Thomas F; Hennebelle I; Delmas C; Lochon I; Dhelens C; Garnier Tixidre C; Bonadona A; Penel N; Goncalves A; Delord JP; Toulas C; Chatelut E
    Clin Pharmacol Ther; 2016 Feb; 99(2):235-42. PubMed ID: 26265035
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Awareness and attitudes of oncology specialists toward dihydropyrimidine dehydrogenase testing in Saudi Arabia.
    Sukkarieh HH; AlSagoor T; Alnuhait M; Bustami R; Bryson S; Adem FMK; Abdalla H; Karbani G
    Cancer Rep (Hoboken); 2023 Feb; 6(2):e1704. PubMed ID: 36806724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Detection of dihydropyrimidine dehydrogenase deficiency before treatment by fluoropyrimidines].
    Gamelin E; Boisdron-Celle M; Morel A
    Therapie; 2007; 62(2):99-103. PubMed ID: 17582309
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treating patients with dihydropyrimidine dehydrogenase (DPD) deficiency with fluoropyrimidine chemotherapy since the onset of routine prospective testing-The experience of a large oncology center in the United Kingdom.
    Wang L; Howlett S; Essapen S
    Semin Oncol; 2022 Apr; 49(2):170-177. PubMed ID: 35027218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Individualized Dosing of Fluoropyrimidine-Based Chemotherapy to Prevent Severe Fluoropyrimidine-Related Toxicity: What Are the Options?
    Knikman JE; Gelderblom H; Beijnen JH; Cats A; Guchelaar HJ; Henricks LM
    Clin Pharmacol Ther; 2021 Mar; 109(3):591-604. PubMed ID: 33020924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Standard-dose tegafur combined with uracil is not safe treatment after severe toxicity from 5-fluorouracil or capecitabine.
    Deenen MJ; Terpstra WE; Cats A; Boot H; Schellens JH
    Ann Intern Med; 2010 Dec; 153(11):767-8. PubMed ID: 21135311
    [No Abstract]   [Full Text] [Related]  

  • 37. Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule.
    Magnani E; Farnetti E; Nicoli D; Casali B; Savoldi L; Focaccetti C; Boni C; Albini A; Banzi M
    Intern Emerg Med; 2013 Aug; 8(5):417-23. PubMed ID: 23585145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential added value of combined DPYD/DPD genotyping and phenotyping to prevent severe toxicity in patients with a
    Ockeloen CW; Raaijmakers A; Hijmans-van der Vegt M; Bierau J; de Vos-Geelen J; Willemsen AE; van den Bosch BJ; Coenen MJ
    J Oncol Pharm Pract; 2023 Jan; 29(1):5-13. PubMed ID: 34797200
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel large intragenic DPYD deletion causing dihydropyrimidine dehydrogenase deficiency: a case report.
    Malekkou A; Tomazou M; Mavrikiou G; Dionysiou M; Georgiou T; Papaevripidou I; Alexandrou A; Sismani C; Drousiotou A; Grafakou O; Petrou PP
    BMC Med Genomics; 2024 Mar; 17(1):78. PubMed ID: 38528593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Dihydropyrimidine dehydrogenase deficiency and toxicity to fluoropyrimidine].
    Boisdron-Celle M; Morel A; Gamelin E
    Ann Biol Clin (Paris); 2010; 68(1):27-32. PubMed ID: 20146975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.